All news from Palliative Medicine

FDA Approves Blincyto Use In ALL

On March 7, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 8-4 in Amgen's favor on the question of whether current research demonstrated a potential benefit for a new use of blinatumomab. The drug has been approved for the treatment of relapsed or refractory BCP ALL in adults and children.